Search Orphan Drug Designations and Approvals
-
Generic Name: | Imatinib mesylate | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Gleevec | ||||||||||||||||
Date Designated: | 08/25/2005 | ||||||||||||||||
Orphan Designation: | Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Novartis Pharmaceuticals Corporation One Health Plaza Mail Code 105/1E870D East Hanover, New Jersey 07936 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | Imatinib mesylate |
---|---|---|
Trade Name: | Gleevec | |
Marketing Approval Date: | 10/19/2006 | |
Approved Labeled Indication: | Treatment of adult patients with hypereosinophic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRÿ}ÿ± fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRÿ}ÿ± fusion kinase negative or unknown | |
Exclusivity End Date: | 10/19/2013 | |
Exclusivity Protected Indication* : | ||
-